SCHEMBL16632624

SCHEMBL16632624

COc1ccccc1Oc1cccc2cc(C#N)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.57
HPGDS O60760 1/20 0.50
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
ACHE P22303 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SLC6A4 P31645 3/20 0.40
ALPL P05186 1/20 0.40
BCL2 P10415 1/20 0.40
MCL1 Q07820 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6100395 0.89 HPGDS (0.56) ARHPGDSCA1CA2ACHE
SCHEMBL16640617 0.88 AR (0.59) ARHPGDSCA1CA2ACHE
SCHEMBL16632568 0.88 AR (0.54) ARHPGDSCA1CA2ACHE
SCHEMBL16632331 0.87 SLC6A4 (0.58) ARHPGDSCA1CA2ACHE
SCHEMBL16632414 0.85 AR (0.53) ARHPGDSACHESMN1; SMN2KDM4E
SCHEMBL16632419 0.83 AR (0.52) ARHPGDSCA1CA2ACHE
SCHEMBL16632510 0.82 CA1 (0.46) ARHPGDSCA1CA2KDM4E
SCHEMBL16632732 0.78 CYP1A2 (0.50) CA1CA2ACHESMN1; SMN2KDM4E
SCHEMBL16632544 0.77 CA12 (0.54) CA1CA2ACHESMN1; SMN2KDM4E
SCHEMBL16632535 0.77 SLC6A2 (0.47) CA1CA2ACHESLC6A4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR AR 3070/4885HPGDS 998/4885CA1 4637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.